MCM
EBS icon

Matarin Capital Management’s Emergent Biosolutions EBS Stock Holding History

Matarin Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1.71M Sell
19,133
-11,350
-37% -$1.04M 0.42% 114
2020
Q3 		$3.15M Sell
30,483
-54,310
-64% -$5.85M 0.66% 67
2020
Q2 		$6.71M Sell
84,793
-14,177
-14% -$1.06M 1.34% 5
2020
Q1 		$5.73M Buy
+98,970
New +$5.7M 0.89% 24
2019
Q3 		– Sell
-143,509
Closed -$6.93M – 255
2019
Q2 		$6.93M Sell
143,509
-227,204
-61% -$10.9M 0.5% 82
2019
Q1 		$18.7M Sell
370,713
-827
-0.2% -$48.8K 1.36% 2
2018
Q4 		$22M Sell
371,540
-1,440
-0.4% -$92.8K 1.78% 1
2018
Q3 		$24.6M Buy
372,980
+33,181
+10% +$1.94M 1.58% 2
2018
Q2 		$17.2M Sell
339,799
-12,031
-3% -$627K 1.24% 5
2018
Q1 		$18.5M Buy
351,830
+26,919
+8% +$1.34M 1.39% 4
2017
Q4 		$15.1M Buy
324,911
+14,705
+5% +$619K 1.18% 7
2017
Q3 		$12.5M Buy
310,206
+47,465
+18% +$1.72M 1.07% 11
2017
Q2 		$8.91M Buy
262,741
+5,075
+2% +$157K 0.82% 32
2017
Q1 		$7.48M Buy
257,666
+29,979
+13% +$913K 0.74% 44
2016
Q4 		$7.48M Buy
227,687
+8,053
+4% +$241K 0.84% 31
2016
Q3 		$6.93M Buy
219,634
+9,830
+5% +$286K 0.76% 39
2016
Q2 		$5.9M Buy
209,804
+287
+0.1% +$11.3K 0.8% 38
2016
Q1 		$7.62M Buy
209,517
+10,737
+5% +$379K 1.06% 13
2015
Q4 		$7.95M Buy
198,780
+23,391
+13% +$816K 1.19% 8
2015
Q3 		$5M Buy
175,389
+73,545
+72% +$2.42M 1.02% 25
2015
Q2 		$3.36M Buy
101,844
+26,464
+35% +$820K 0.96% 23
2015
Q1 		$2.17M Sell
75,380
-7,172
-9% -$206K 0.66% 65
2014
Q4 		$2.25M Sell
82,552
-2,451
-3% -$58.4K 0.99% 27
2014
Q3 		$1.81M Sell
85,003
-743
-0.9% -$17K 0.83% 44
2014
Q2 		$1.93M Buy
85,746
+14,630
+21% +$341K 0.86% 45
2014
Q1 		$1.8M Sell
71,116
-5,421
-7% -$137K 1.06% 22
2013
Q4 		$1.76M Buy
76,537
+36,071
+89% +$752K 1.08% 40
2013
Q3 		$771K Buy
40,466
+5,567
+16% +$99.4K 0.65% 68
2013
Q2 		$503K Buy
+34,899
New +$505K 0.51% 80

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Matarin Capital Management's EBS Position: Q4 2020 in Review

Matarin Capital Management reduced its Emergent Biosolutions (EBS) stake by 37% in Q4 2020, selling an estimated $1.04M and leaving 19,133 shares worth $1.71M. The position accounts for 0.42% of the portfolio, ranked #114.

Matarin Capital Management first reported a position in EBS in Q2 2013 and has held it in 29 quarters since. The position peaked at $24.6M in Q3 2018. 353 funds tracked by Wall St. Rank hold EBS as of Q4 2020.

  • Matarin Capital Management held 19,133 shares of Emergent Biosolutions worth $1.71M as of Q4 2020.
  • Matarin Capital Management sold 11,350 Emergent Biosolutions shares in Q4 2020, an estimated $1.04M.
  • Emergent Biosolutions made up 0.42% of Matarin Capital Management's portfolio in Q4 2020, its #114 holding.
  • Matarin Capital Management first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 29 quarters since.
  • Matarin Capital Management's Emergent Biosolutions position peaked at $24.6M in Q3 2018.
  • 353 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2020.

Based on Matarin Capital Management's 13F filing for Q4 2020, filed 3 Feb 2021.